Overexpression of CIP2A is associated with poor prognosis in multiple myeloma
Sign Up to like & getrecommendations! Published in 2017 at "Signal Transduction and Targeted Therapy"
DOI: 10.1038/sigtrans.2017.13
Abstract: Cancerous inhibitor of protein phosphatase 2A (CIP2A), an endogenous protein phosphatase 2A (PP2A) inhibitor, has been identified as an oncoprotein in promoting cancer initiation and progression of several types of cancer. However, the expression and… read more here.
Keywords: overexpression cip2a; prognosis; cip2a; multiple myeloma ... See more keywords
Prognostic significance of CIP2A expression in solid tumors: A meta-analysis
Sign Up to like & getrecommendations! Published in 2018 at "PLoS ONE"
DOI: 10.1371/journal.pone.0199675
Abstract: CIP2A, cancerous inhibitor of protein phosphatase 2A, was initially recognized as an oncoprotein. Recently several studies revealed that CIP2A could function as a prognosis biomarker, however, the result remained not comprehensive, partly due to small… read more here.
Keywords: cip2a expression; solid tumors; cip2a; meta analysis ... See more keywords
Cancerous inhibitor of protein phosphatase 2A enhances chemoresistance of gastric cancer cells to oxaliplatin
Sign Up to like & getrecommendations! Published in 2023 at "World Journal of Gastrointestinal Oncology"
DOI: 10.4251/wjgo.v15.i2.286
Abstract: BACKGROUND Cancerous inhibitor of protein phosphatase 2A (CIP2A) is a newly discovered oncogene. It is an active cell proliferation regulatory factor that inhibits tumor apoptosis in gastric cancer (GC) cells. CIP2A is functionally related to… read more here.
Keywords: chemoresistance; cip2a expression; cells oxaliplatin; cip2a ... See more keywords